External broker reports(aggregated public sources), Taylor Collison

Taylor Collison

External broker reports(aggregated public sources)

Taylor Collison is a leading financial services firm, providing advice & wealth creation strategies to private & institutional investors and corporate clients throughout Australia. Content available is external broker reports authored by a third party outside the Smartkarma network and has been aggregated by an online aggregator through publicly available sources and is displayed by Smartkarma in this format for user's convenience and general informational purposes only. Content does not constitute investment or financial advice and Smartkarma makes no representation or warranty regarding its accuracy or contents. Original third party author retains all copyright and other proprietary rights in the content. Access or use of third party links not controlled by Smartkarma are at the user's own risk.

Equity Bottom-Up

<ul><li>IMM reported positive headline data from its expanded TACTI-002 part A trial in first line (1L) non small cell lung cancer (NSCLC) at ASCO last week.</li><li>The overall response rate (ORR) among all 114 subjects treated with the efti/Keytruda combo edged higher to 38.6% vs 36.1% in the first 36 at ASCO 2021.</li><li>Consistent with the trends seen in the different PD-L1 tumour biomarker subgroups in the first 36 patients last year, the greatest of the benefit of efti was seen in the PD-L1low (TPS 1-49%) group, and to a lesser extent in PD-L1negative patients.</li></ul><p><em>Content is external broker report sourced from online content aggregator through publicly available sources and is displayed below for general informational purposes only. Refer full disclaimer below.</em></p>

IMM reported positive headline data from its expanded TACTI-002 part A trial in first line (1L) non small cell lung cancer (NSCLC) at ASCO last week.The overall response rate (ORR) among all 114 subjects treated with the efti/Keytruda combo edged higher to 38.6% vs 36.1% in the first 36 at ASCO 2021.Consistent with the trends seen in the different PD-L1 tumour biomarker subgroups in the first 36 patients last year, the greatest of the benefit of efti was seen in the PD-L1low (TPS 1-49%) group, and to a lesser extent in PD-L1negative patients.Content is external broker report sourced from online content aggregator through publicly available sources and is displayed below for general informational purposes only. Refer full disclaimer below.

Immutep (IMM): Lung May Jump Breast Cancer in Trial Queue

Australia

Immutep Limited operates as a biotechnology company. The Company focuses on developing novel immunotherapy treatments for cancer and autoimmune disease. Immutep offers its services worldwide.

Price Gauge
52-week Range	0.00 - 0.00
Market Cap (USDm)	0.00
P/E	0.00
Dividend (Yield)	0.00